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It has become increasingly evident that in certain pathological states, AMPAR expression is compromised, resulting in alterations to synaptic function. CP-AMPARs in particular have well-established roles in epilepsy Rajasekaran et al., 2012; Malkin et al., 2016) , ischaemia (Kwak and Weiss, 2006) , traumatic brain injury (Spaethling et al., 2008) , and illicit substance addiction and withdrawal (Pistillo et al., 2016; Wolf, 2016) . Indeed, the contribution of CP-AMPARs to these disease etiologies has been thoroughly reviewed (Tanaka et al., 2000; Liu and Zukin, 2007; Henley and Wilkinson, 2016) and the potential for targeting AMPARs as a therapeutic strategy continues to be explored (Chang et al., 2012; Franco et al., 2013; Zaccara and Schmidt, 2016) . In addition to these diseases, it has been postulated that CP-AMPARs might also contribute to progressive neurodegeneration (Weiss and Sensi, 2000; Kwak and Weiss, 2006) . However, until recently, there has been limited evidence to support this claim. Thus, this review will discuss recent evidence implicating CP-AMPARs in Alzheimer's Disease (AD), and describe how targeting AMPARs may offer a potential therapeutic strategy in treating AD patients.
Ca 2þ
-permeable AMPA receptors: structure, function and expression a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) are ionotropic receptors, formed by the tetrameric assembly of GluA1-4 subunits, and are widely expressed throughout the central nervous system (Hollmann and Heinemann, 1994) . AMPARs are highly dynamic complexes, being able to transition between different subunit assembles depending on the synaptic environment (Schwenk et al., 2014; Herguedas et al., 2016) . In the adult hippocampus, AMPARs are typically composed of a combination of GluA1 and GluA2, or GluA2 and GluA3 subunits (Wenthold et al., 1996) . The AMPAR subunits themselves have four distinct domains: an N-terminal extracellular domain; a ligand binding domain (composed of two extracellular polypeptide sections, termed S1 and S2 (Keinanen et al., 1990; Stern-Bach et al., 1994) ); a membrane-localised channel domain (formed by three transmembrane a-helices and a channel pore loop, termed M1, M2, M3 and M4); and an intracellular C-terminal domain (Fig. 1) .
The functional properties of AMPARs depend on the composition of its subunits. For instance, inclusion of the GluA2 subunit in a receptor confers Ca 2þ impermeability and these are the major species of receptor found in glutamatergic neurons (Wenthold et al., 1996) . The impermeability to Ca 2þ is conferred by editing of the Q/R site of GluA2 pre-mRNA. Here, a glutamine (Q) codon (which lies within the channel-forming M2 re-entrant membrane loop region) is modified into an arginine (R) codon (Sommer et al., 1991; Burnashev et al., 1992) . However, AMPARs can be Ca 2þ permeable in certain circumstances; (1) in the instances where they contain unedited GluA2(Q) subunits, or (2) when they are formed without the inclusion of the GluA2 subunit. GluA2-lacking AMPARs, which are often homomeric for the GluA1 subunit, are termed Ca 2þ -permeable AMPARs (CP-AMPARs). CP-AMPARs are known to have greater single channel conductance than GluA2-containing AMPARs (Swanson et al., 1997) , though less than Nmethyl-D-aspartate receptors (NMDARs) (Dingledine et al., 1999) . Additionally, CP-AMPARs have faster desensitization constants than GluA2-containing receptors (Traynelis et al., 2010) The majority of CP-AMPARs display an inwardly rectifying current-voltage relationship (though see Gilbertson et al., 1991) , whereby the receptors do not permit the passage of current at depolarising membrane potentials, due to channel pore blockade by intracellular polyamines (Bowie and Mayer, 1995; Donevan and Rogawski, 1995; Guerra et al., 2016) ; ( Fig. 2A, B ). This change in rectification properties conferred by endogenous intracellular polyamines is, however, subject to regulation by the AMPAR auxiliary subunit stargazin (Soto et al., 2007) . Stargazin reduces the sensitivity of CPAMPARs to polyamine block, as well as increasing single-channel conductance and slowing deactivation of receptors, altogether increasing the influx of Ca . This regulation of channel properties by stargazin may increase the functional diversity of CP-AMPARs, with populations of CP-AMPARs in regions where stargazin is not expressed displaying altered functional characteristics. The wideranging effects that external and internal polyamines have on AMPAR channel conductance, and contrasting data obtained from bi-polar retinal cells, has led some to question whether GluA2-containing AMPARs can actually display Ca 2þ -permeable characteristics (Bowie, 2012) . Thus, it is highly evident that further investigation is required to substantiate the exact composition of the different populations of AMPARs. Expression of CP-AMPARs is evident during the early developmental stages of the hippocampus, compared to just a small fraction of CP-AMPARs present in mature hippocampal neurons (Wenthold et al., 1996; Rozov et al., 2012) . This is in part due to the presence of unedited forms of GluA2 mRNA at embryonic stages, which later become almost entirely obsolete as the brain reaches maturity (Burnashev et al., 1992; Kawahara et al., 2003) . Coupled with a higher ratio of GluA1, GluA3, and GluA4 to GluA2 subunits, CP-AMPARs are known to be relatively prevalent in the hippocampus during the first few postnatal weeks (PellegriniGiampietro et al., 1992; Ho et al., 2007) . However, a subsequent increase in edited GluA2 subunit expression can be seen after approximately 1e3 weeks of postnatal development (PellegriniGiampietro et al., 1992; Pickard et al., 2000; Ho et al., 2007; Blair et al., 2013) . A similar profile is found in other brain regions, where low GluA2 abundance in early developmental stages results in CP-AMPAR expression in neonatal neurons of the cortex, striatum and cerebellum, which gradually declines after a short developmental time window (Pellegrini-Giampietro et al., 1992; Kumar et al., 2002; Shin et al., 2007; Miyazaki et al., 2012) . Other findings have shown that CP-AMPARs emerge at later time points in certain cell-types, replacing Ca 2þ -impermeable AMPARs in fast spiking interneurons of the prefrontal cortex during adolescence (Wang and Gao, 2010) . Thus, the expression of CP-AMPAR is tightly regulated and linked to developmental stages, brain regions and distinct cell-types. and an intracellular Cterminal domain (CTD), three transmembrane domains (M1, M3, M4) and a channel pore loop (M2). The alternately spliced flip/flop site encodes a short amino-acid sequence within an extracellular domain of the AMPAR subunit and the Q/R editing site is shown within the channel pore loop. Depending on the AMPAR subunit, the CTD may be either short or long-tailed, which alters the trafficking properties and interacting partners of AMPARs. Shown are the AMPAR CTD binding proteins 4.1N, synapseassociated protein 97 (SAP97), post synaptic density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein (zo-1) (PDZ), N-ethylmaleimide-sensitive factor (NSF), Glutamate receptor-interacting protein (GRIP), and protein that interacts with protein C-kinase 1 (PICK1).
Physiological roles of Ca 2þ
-permeable AMPA receptors at the synapse Though limited in their expression in the mature synapse, CPAMPARs are nevertheless thought to play important roles in the physiological function of neurons. AMPARs are pivotal in both the induction and expression of plasticity events that occur during synaptic stimulation (Henley and Wilkinson, 2016) . The insertion of AMPARs at the synapse is an underlying molecular mechanism of long-term potentiation (LTP), a form of synaptic plasticity widely considered to be a correlate of learning and memory at the molecular level (Bliss and Collingridge, 1993) . Whilst it was initially thought that only heteromeric assemblies of AMPARs containing both GluA1 and GluA2 subunits were trafficked to the synaptic membrane of CA1 pyramidal neurons during synaptic stimulation, later studies have shown that expression of LTP requires the insertion of CP-AMPARs under certain circumstances, but that their expression is transient (<25 min) in nature (Jia et al., 1996; Plant et al., 2006; Jaafari et al., 2012; Park et al., 2016) . It is however, debatable whether CP-AMPARs are expressed during LTP induction (Adesnik and Nicoll, 2007; Gray et al., 2007) . Whilst these two studies bring in to question the importance of CP-AMPARs in the induction of synaptic plasticity, a possible explanation for these contradictory results may be related to the age of animal and . In contrast, LTP in animals closer to 3 weeks of age was insensitive to IEM-1460 treatment, illustrating the small time frame in which CPAMPARs may contribute to synaptic plasticity. Here, we will not cover this debate further since it is beyond scope of this review, however it is clear that further work is required to fully understand the specific circumstances where CP-AMPARs are pivotal for plasticity induction.
We have recently shown that in addition to possible roles in the induction of LTP per se, CP-AMPARs might also confer metaplastic properties to hippocampal neurons. We reported that acute stress or brief application of the GR agonist dexamethasone (DEX) results in a long-lasting increase in synaptic potentiation, which is mediated through the insertion of CP-AMPARs at the synaptic membrane (Whitehead et al., 2013) (Fig. 3) . We showed that, whilst this stress-induced increase in LTP was, in part, mediated through activation of NMDARs, a portion of synaptic potentiation was found to be sensitive to treatment with IEM-1460, indicating the involvement of CP-AMPARs. Moreover, acute stress resulted in an inwardly rectifying current/voltage (I/V) relationship, which is indicative of increased CP-AMPAR surface expression. We also found that the expression of CP-AMPARs required the protein kinase A (PKA)-mediated phosphorylation of the GluA1 serine 845 residue (S845), a known mechanism regulating CP-AMPAR synaptic expression (He et al., 2009) . Consistent with our findings, a recent report has noted that acute footshock stress results in the rapid upregulation of S845 GluA1 phosphorylation, suggestive of the increased incorporation/stabilization of GluA1-containing AMPARs (Bonini et al., 2016) . Further, phosphorylation of GluA1 at the serine 831 residue (S831) was found to occur under certain circumstances following acute swim stress (Fumagalli et al., 2012) , which robustly increases single channel conductance (Kristensen et al., 2011) . Taken together, these results suggest that CP-AMPARs can rapidly respond to environmental stimuli in order to regulate synaptic transmission and function.
Interestingly, whilst the findings of CP-AMPARs in acute stress might suggest a role in enhancing memory or learning, conversely, CP-AMPARs have also been shown to also be important in memory erasure (Clem and Huganir, 2010) . During the consolidation period following fear memory conditioning, expression of CP-AMPARs in the amygdala was found to be increased, which resulted in a greater magnitude of the long-term depression (LTD) form of synaptic plasticity and increased chance of memory extinction. Thus, it appears that CP-AMPARs can regulate both forms of synaptic activity e LTP and LTD. For example, it was shown that CP-AMPARs are recruited to the synaptic membrane during LTD induction, through activation of PKA anchored to a kinase anchor protein 150 (AKAP150), and phosphorylation of S845 on the GluA1 subunit . Whilst LTD could be induced by NMDARs alone, the magnitude of LTD was smaller compared to when CPAMPARs were expressed. Clearly then, CP-AMPARs can have a multitude of roles in normal physiological function of neurons. It is of interest therefore whether the molecular mechanisms that regulate CP-AMPARs are differentially regulated in pathological conditions in the brain.
Potential role of Ca 2þ
-permeable AMPA receptors in Alzheimer's disease
In an examination of postsynaptic density-rich fractions of human AD patients' hippocampus, an increase in GluA1 levels was reported when compared with healthy control patients, whereas no changes to NMDAR subunit expression were observed (Marcello et al., 2012) . This suggests a selective increase in GluA1-containing receptors at synapses in the AD hippocampus. Consistent with this, we have recently shown that direct infusion of oligomerised amyloid-b (Ab) -thought to be a key driving force in AD pathogenesis (LaFerla et al., 2007) -into CA1 hippocampal neurons resulted in a rapid synaptic insertion of CP-AMPARs . This effect enhances AMPAR-mediated excitatory postsynaptic current (EPSC AMPA ) and was absent in cells treated with IEM-1460 or in cells transfected with shRNA directed against the GluA1 AMPAR subunit. We also showed that these effects operate through PKA-mediated S845 GluA1 phosphorylation (see Fig. 4 ) suggesting that Ab utilises a canonical mechanism of CP-AMPAR expression. In addition, a recent study of an AD transgenic mouse model reported aberrant CP-AMPAR expression and increased GluA1 phosphorylation specifically in young mice, prior to any overt neuropathology (Megill et al., 2015) . Together, these findings indicate that CP-AMPAR synaptic insertion may be an early-stage event in AD pathogenesis.
What is currently missing in our understanding of CP-AMPAR function in AD pathology is how the expression of the receptor might translate into pathological consequences for the neuron. A compelling hypothesis is that aberrant CP-AMPAR expression causes excessive intracellular Ca 2þ influx that leads to synaptic dysfunction and neurodegeneration. Physiologically, CP-AMPARs appear to be only transiently expressed in response to synaptic activity (Plant et al., 2006; Sutton et al., 2006; Hou et al., 2008; Yang et al., 2010) . If this is case, CP-AMPAR expression is tightly regulated as a physiological necessity, and this likely provides a mechanism that protects against aberrant and/or sustained Ca 2þ flux through CP-AMPARs in excitatory synapses. Therefore, it is likely that aberrant activation of CP-AMPAR function may elicit Ca 2þ -mediated synaptic and neuronal degeneration. Indeed, alterations in Ca 2þ homeostasis have been proposed to be crucial in the initial stages of AD development (LaFerla, 2002) . Changes to Ca 2þ signaling have been linked to dysregulation of amyloid precursor protein (APP) processing, responsible for Ab production, and may augment the formation of toxic Ab oligomers (Mattson, 1990; Mattson et al., 1993) . Indeed, the increased production of Ab oligomers in AD patients has been attributed to the higher incidence of epileptic seizures, especially in patients in the early stages of disease (Amatniek et al., 2006) . It is also worth considering the overt link between CP-AMPAR expression and aberrant neuronal network activity that is prevalent in epilepsy (Rajasekaran et al., 2012) , in the context of the seizure activity and cognitive impairments that are evident in APP transgenic mouse models and AD patients (Palop et al., 2007; Pandis and Scarmeas, 2012) . These findings support the notion that dysregulated Ca 2þ flux through sustained CP-AMPAR expression in early phases of AD may accelerate the onset of neuronal network dysfunction and neuronal excitotoxicity, thus propagating cognitive decline (Palop and Mucke, 2009) , though it remains to be seen whether CP-AMPARs are expressed solely at these initial stages of pathology, or again at a later point in the disease cycle. Aberrant synapse weakening, which promotes the elimination of synaptic connections, also appears to be an underlying feature of several neuropathological conditions (Hasbani et al., 2000; Bradley et al., 2012; Sheng et al., 2012; Park and Biederer, 2013) . Synapse weakening processes involve a number of specific catalyzing signals (Collingridge et al., 2010) . We have recently identified the activation of caspase-3 and glycogen synthase kinase-3b (GSK-3b), and phosphorylation of the microtubule associated protein tau (pTau), as being pivotal and necessary end-point signals in synapse weakening (Kimura et al., 2014; Regan et al., 2015 Regan et al., , 2016 . Critically, aberrantly enhanced pTau is a common factor to synapse dysregulation and weakening induced by a variety of factors, including Ab, stress and neurotrophins (Sotiropoulos et al., 2011; Pooler et al., 2014; Kailainathan et al., 2016) . Given the aforementioned importance of CP-AMPAR expression to the initial synaptic alterations induced by stress and Ab (Whitehead et al., 2013; Whitcomb et al., 2015) , one favourable hypothesis is that CP-AMPAR expression leads to aberrant synapse weakening via the activation of signaling pathways culminating in pTau. Interestingly, synaptic activity leading to accumulation of intracellular Ca 2þ has been shown to increase pTau at serine residues 396/404 (S396/404), via Ca 2þ -dependent activation of GSK-3b (Pierrot et al., 2006) . In addition, hyperphosphorylation of tau has been linked to abnormal Ca 2þ signaling through excitotoxic levels of glutamate (Guo et al., 1999; Leissring et al., 2000) , and this dysregulated Ca 2þ could serve as the conduit between CP-AMPAR expression and pTau. Further work is therefore required to fully determine the potential role of CPAMPARs in synapse weakening pathways including pTau and other substrates.
Conclusion and translation
Neurodegenerative diseases such as AD are currently without effective treatments or cures (Casey et al., 2010) . Given the growing evidence implicating CP-AMPARs in the onset of synaptic pathology Kwak and Weiss, 2006; Rajasekaran et al., 2012; Whitcomb et al., 2015) , this form of AMPAR could well serve as a therapeutic target in the development of new treatments in AD and other neurodegenerative diseases. Indeed, targeting CPAMPARs has been cited as a potential strategy in other neurological disorders (Henley and Wilkinson, 2016) . However, in order to effectively develop novel methodologies to modulate CP-AMPAR function in disease, we first require an understanding of the mechanisms by which CP-AMPARs aberrantly function, and the downstream consequences. In doing so, meaningful approaches in the development of CP-AMPAR regulators can be undertaken. Two non-competitive inhibitors of AMPA receptors, talampanel and perampanel, have shown some efficacy in reducing seizure activity in clinical trials (Chappell et al., 2002; Kerling and Kasper, 2013) and have been shown to reduce neuronal Ca 2þ elevations in cultured neurons (Hanada et al., 2011; Paizs et al., 2011) . However, whether these antagonists might prove to be a useful therapeutic strategy for AD remains to be seen. A promising strategy for limiting the progression of the disease could involve the development of a highly selective, bioavailable CP-AMPAR antagonist administered at an early, pre-symptomatic stage of AD.
